🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million instances each year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the context of rising global incidence, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are increasingly worried about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to results released by a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The trial included over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in many low-income and middle-income countries.

Clinicians directly involved have expressed hope. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for public health efforts. This is considered essential to reduce the burden of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.